Conversion of somatic cells to induced reprogrammed neural stem cells (irNSCs)

Patent metadata

Field	Value
Publication number	US-9297025-B2
Application number	US-201313769762-A
Country	US
Kind code	B2
Filing date	Feb 18, 2013
Priority date	Aug 19, 2010
Publication date	Mar 29, 2016
Grant date	Mar 29, 2016

Abstract

This application relates to a method for converting somatic cells to Neural Stem Cells (NSCs). Moreover this application relates to a method for converting human fibroblasts, keratinocytes or adipocytes to neural stem cells based on linked steps of genes transduction and chemically defined medium induction.

First claim

What is claimed:

1. A method of producing Neural Stem Cells (NSCs), comprising:
a) providing human somatic cells selected from the group consisting of fibroblasts, adipocytes, or keratinocytes,
b) reprogramming said cells to NSCs by introducing a first and a second gene, wherein the first gene is Sox2, and the second gene is selected from the group consisting of Bmi1, Mash 1, Sox11, Emx2, Foxg1 and Pax6; and
c) culturing the cells of step (b) in medium comprising growth factors selected from the group consisting of FGF2, EGF and BDNF and a small molecule inhibitor of Rho-associated coiled-coil forming protein serine/threonine kinase (ROCK inhibitor), to produce NSCs.

2. The method of claim 1 , further comprising
d) incubating the NSCs under conditions suitable for proliferation of the NSCs.

3. The method of claim 1 , wherein said cells of step a) are fibroblasts.

4. The method of claim 1 , wherein the growth factors and small molecule of step c) are supplements of a chemically defined medium.

5. The method of claim 4 , wherein the chemically defined medium is a serum free medium supplemented with insulin, transferrin and progesterone.

6. The method of claim 1 , wherein the second gene of step b) is Bmi1.

7. The method of claim 6 , wherein a third gene is introduced into the cells of step b) and the third gene is selected from the group of Mash1, Sox11, Emx2, Foxg1 and Pax6.

8. The method of claim 7 , wherein the third gene of step b) is Mash1.

9. The method of claim 1 , wherein the ROCK inhibitor is selected from the group consisting of 1-(5-Isoquinolinesulfonyl) homopiperazine, N-Benzyl-2-(pyrimidin-4-ylamino)thiazole-4-carboxamide, (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl) cyclo-hexanecarboxamide dihydrochloride) and N-{(3R,4R)-4-[4-(2-Fluoro-6-hydroxy-3-methoxy-benzoyl)-benzoylamino]-azepan-3-yl}-4-hydroxy-3,5-dimethyl-benzamide.

10. The method of claim 1 , wherein the somatic cells are pretreated with a histone deacetylase (HDAC) inhibitor.

11. The method of claim 1 , wherein reprogramming of said somatic cells is achieved through delivery of a combination of at least two genes by a lentivirus.

12. A method of producing Neural Stem Cells (NSCs), comprising:
a) providing human somatic cells selected from fibroblasts, keratinocytes and adipocytes;
b) pretreating the human somatic cells with a histone deacetylase (HDAC) inhibitor;
c) reprogramming said human somatic cells to NSCs by introducing the genes Bmi1 and Sox2 and optionally at least one gene selected from the group consisting of Mash1, Sox11, Emx2, Foxg1 and Pax6, such introduction optionally effected by a lentivirus;
d) culturing the cells of step (c) in medium comprising at least one growth factor selected from the group consisting of FGF2, EGF and BDNF, and a small molecule ROCK inhibitor selected from the group consisting of 1-(5-Isoquinolinesulfonyl) homopiperazine, N-Benzyl-2-(pyrimidin-4-ylamino)thiazole-4-carboxamide, (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl) cyclo-hexanecarboxamide dihydrochloride) and N-{(3R,4R)-4-[4-(2-Fluoro-6-hydroxy-3-methoxy-benzoyl)-benzoylamino]-azepan-3-yl}-4-hydroxy-3,5-dimethyl-benzamide to produce NSCs; and
e) incubating the product of steps c) and d) under conditions suitable for proliferation of the NSCs.

Assignees

• Hoffmann La Roche

Inventors

• Christensen Klaus
• Graf Martin
• Iacone Roberto
• Jagasia Ravi

Classifications

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C12N2501/602

  Sox-2 · CPC title

• C12N2501/115

  Basic fibroblast growth factor (bFGF, FGF-2) · CPC title

• C12N5/0623 Primary

  Stem cells · CPC title

• C12N2501/405

  Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases · CPC title